Scienture Holdings secures $1.2 million in bridge funding

NEW YORK - Scienture Holdings, Inc. (NASDAQ:SCNX) announced Thursday it has secured approximately $1.2 million in bridge funding through the issuance of common stock to institutional or accredited investors. The funding comes as the company, currently valued at $27.15 million, faces challenging financial metrics with negative EBITDA of -$12.78 million in the last twelve months.

The company’s board of directors approved a total bridge funding raise of up to $3 million. According to the company’s statement, the funding does not include warrants, options, or other convertible securities that could dilute existing stockholders.

Scienture Holdings plans to use the capital to support upcoming commercial product launches and pipeline program development efforts.

"Obtaining the bridge funding on the most favorable terms possible is crucial as we enter a critical moment in the Company’s history," said Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer.

Narasimhan Mani, Co-Chief Executive Officer and President, added that the commitment would help enable the company to "unlock stockholder value" as it executes its near-term business strategy.

Scienture Holdings is a pharmaceutical company focused on developing and distributing specialty products for unmet market needs. The company operates through its wholly owned subsidiaries, including Scienture, LLC.

The information in this article is based on a company press release statement.

In other recent news, Scienture Holdings, Inc. has announced that it has regained compliance with Nasdaq’s minimum bid price requirement. The company achieved this milestone after its stock traded above $1.00 per share for ten consecutive business days. This development comes after Scienture received a notification from Nasdaq on May 19, 2025, regarding its non-compliance with the exchange’s listing rule. Additionally, Scienture Holdings has terminated its Equity Line of Credit (ELOC) facility, effective May 22, 2025. The company has filed a post-effective amendment to deregister all 310,488 unsold shares of common stock that were part of the facility. The original registration statement for this facility was filed in December 2025 and became effective on February 14, 2025. These recent developments indicate significant financial and strategic adjustments by Scienture Holdings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.